Aripiprazole (Abilify)
Third-generation atypical antipsychotic with a unique mechanism as a dopamine D2/D3 partial agonist and 5-HT1A partial agonist / 5-HT2A antagonist. Stabilizes dopamine activity, reduces it in hyperdopaminergic states (psychosis) and enhances it in hypodopaminergic states. Active metabolite dehydro-aripiprazole has similar D2 affinity. Very long combined half-life allows once-daily dosing. Used for schizophrenia, bipolar I, MDD augmentation, and irritability in autism.
Projected serum levels — 10 mg, once daily
Maintenance schedule: 10 mg once daily (oral).
Loading schedule: 26.4 mg on day 1, then 10 mg once daily — reaching therapeutic levels sooner.
Modeled steady state after ~10 days: peak ≈ 17.0 mg, trough ≈ 10.8 mg body load. Population-based estimate over 25 days for a 10 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Antipsychotic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 3.1 days
- Common dose
- 10 mg
- Suggested maximum
- 30 mg/day
- Reference dose range
- 5–30 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 15 mg oral — Cmax 0.15 mg/L at 3 h
Documented interactions
-
contraindicated
Efavirenz (Sustiva) + Aripiprazole (Abilify)
Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Aripiprazole (Abilify) AUC by ~0.20x
-
contraindicated
Rifampin + Aripiprazole (Abilify)
Rifampin inducer of CYP3A4 predicted to change Aripiprazole (Abilify) AUC by ~0.20x
-
danger
1P-LSD (1-Propionyl-LSD) + Aripiprazole (Abilify)
1P-LSD (1-Propionyl-LSD) and Aripiprazole (Abilify) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
25I-NBOMe + Aripiprazole (Abilify)
25I-NBOMe and Aripiprazole (Abilify) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Aripiprazole (Abilify)
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Aripiprazole (Abilify) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Aripiprazole (Abilify)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Aripiprazole (Abilify) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…
Serum checks 358 modeled interaction pairings for aripiprazole (abilify) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Aripiprazole augmentation of antidepressant therapy in treatment-resistant depression: a double-blind, placebo-controlled study
Pivotal RCT (362 patients) demonstrating aripiprazole 2-20 mg/day augmentation of SSRIs/SNRIs produced significantly greater improvement in depression scores versus placebo, with remission rate of 26% versus 16%.
-
Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder
Phase III RCT establishing aripiprazole 30 mg/day as significantly superior to placebo for acute mania, with Y-MRS improvement of -8.2 points versus -3.4 for placebo at day 21.
-
Population pharmacokinetics of aripiprazole and dehydro-aripiprazole
Population PK analysis establishing aripiprazole half-life of 75 hours, active metabolite dehydro-aripiprazole half-life of 94 hours, CYP2D6/3A4-dependent metabolism, and steady-state achievement in 14 days.
3 published studies referenced in the app, each with a plain-language summary.